A patented technology called CIVO enables simultaneous testing of multiple cancer drugs in a patient's tumor, accurately predicting systemic response. This innovation has shown positive findings using multiple cancer drugs tested in xenografted mouse models and canine patients.
Onconova Therapeutics presents updated clinical trial results for Estybon (ON 01910.Na) in patients with myelodysplastic syndromes, showing increases in overall survival and bone marrow blast responses. Additionally, ON 013105, a Cyclin D1 inhibitor, demonstrates efficacy in nonclinical models of mantle cell lymphoma.
Onconova Therapeutics has agreed with the FDA on a Special Protocol Assessment (SPA) for its Phase 3 trial of Estybon in patients with myelodysplastic syndromes. The trial is expected to begin in Q4 2010 and will compare Estybon to Best Supportive Care.
Ex-RAD shows significant radioprotective benefit in mice exposed to lethal whole body irradiation, with oral administration producing a high survival rate. The study demonstrates the ability of Ex-RAD to provide radioprotective benefit by injection and oral delivery.